Unity Biotechnology, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Unity Biotechnology, Inc. is seeking stockholder approval for its complete liquidation and dissolution following the cessation of all clinical development and an inability to find viable strategic alternatives.
Unity Biotechnology, Inc. has issued a single Series A Preferred Share to its sole director, granting it 600 million votes to ensure the proportional approval of the company's planned dissolution.
DEFA14A: Unity Biotechnology Issues Preferred Stock to Facilitate Dissolution Vote Amid Nasdaq Delisting
Unity Biotechnology, Inc. has issued a single share of Series A Preferred Stock to its sole director, Craig R. Jalbert, with significant voting power to ensure the passage of its planned dissolution proposal.
Unity Biotechnology has filed a definitive proxy statement with the Securities and Exchange Commission.
Unity Biotechnology will hold its Annual Meeting of Stockholders virtually on June 21, 2024, to vote on director elections, auditor ratification, executive compensation, and say-on-pay frequency.